Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification.
Elkrief A, Odintsov I, Markov V, Caeser R, Sobczuk P, Tischfield SE, Bhanot U, Vanderbilt CM, Cheng EH, Drilon A, Riely GJ, Lockwood WW, de Stanchina E, Tirunagaru VG, Doebele RC, Quintanal-Villalonga Á, Rudin CM, Somwar R, Ladanyi M.
Elkrief A, et al. Among authors: riely gj.
J Thorac Oncol. 2023 Sep;18(9):1165-1183. doi: 10.1016/j.jtho.2023.05.007. Epub 2023 May 13.
J Thorac Oncol. 2023.
PMID: 37182602